Insights from the Miami Breast Cancer Conference Archives

First-line palbociclib plus letrozole demonstrated significant efficacy in patients with ER-positive, HER2-negative breast cancer.
The discovery of crosstalk between HER2 and HR pathways has led to the promising strategy of dual targeting regimens.
Ribociclib improves PFS in premenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer.
Stay in the know.
OncNet Newsletter